Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.

Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations.

Arthritis Rheumatol. 2019 Aug 5. doi: 10.1002/art.41068. [Epub ahead of print]

PMID:
31379105
2.

Histologic predictors of invasion in partially biopsied lentigo maligna melanoma.

Aouidad I, Fargeas C, Romero P, Sei JF, Chaussade V, Beauchet A, Clerici T, Zimmermann U, Saiag P, Funck-Brentano E.

J Am Acad Dermatol. 2019 Apr;80(4):1150-1152. doi: 10.1016/j.jaad.2018.10.036. Epub 2018 Oct 26. No abstract available.

PMID:
30879481
3.

A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma.

Einarsdottir BO, Karlsson J, Söderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, Brynjolfsson SF, Bagge RO, Carstam L, Scobie M, Koolmeister T, Wallner O, Stierner U, Berglund UW, Ny L, Nilsson LM, Larsson E, Helleday T, Nilsson JA.

Cell Death Dis. 2018 Jul 24;9(8):810. doi: 10.1038/s41419-018-0865-6.

4.

Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients.

Roger A, Finet A, Boru B, Beauchet A, Mazeron JJ, Otzmeguine Y, Blom A, Longvert C, de Maleissye MF, Fort M, Funck-Brentano E, Saiag P.

Oncoimmunology. 2018 Mar 13;7(7):e1442166. doi: 10.1080/2162402X.2018.1442166. eCollection 2018.

5.

Variation of mutant allele frequency in NRAS Q61 mutated melanomas.

Hélias-Rodzewicz Z, Funck-Brentano E, Terrones N, Beauchet A, Zimmermann U, Marin C, Saiag P, Emile JF.

BMC Dermatol. 2017 Jul 1;17(1):9. doi: 10.1186/s12895-017-0061-x.

6.

Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.

Boespflug A, Funck-Brentano E, Hélias-Rodzewicz Z, Maucort-Boulch D, Beauchet A, Bringuier PP, Dumontet C, Emile JF, Saiag P, Dalle S.

Pigment Cell Melanoma Res. 2017 Sep;30(5):498-500. doi: 10.1111/pcmr.12606. Epub 2017 Jul 23. No abstract available.

PMID:
28627072
7.

EMMPRIN/CD147 is an independent prognostic biomarker in cutaneous melanoma.

Caudron A, Battistella M, Feugeas JP, Pages C, Basset-Seguin N, Mazouz Dorval S, Funck Brentano E, Sadoux A, Podgorniak MP, Menashi S, Janin A, Lebbé C, Mourah S.

Exp Dermatol. 2016 Aug;25(8):618-22. doi: 10.1111/exd.13022. Epub 2016 May 20.

PMID:
27060463
8.

Increase in NRAS mutant allele percentage during metastatic melanoma progression.

Funck-Brentano E, Hélias-Rodzewicz Z, Longvert C, Mokhtari K, Saiag P, Emile JF.

Exp Dermatol. 2016 Jun;25(6):472-4. doi: 10.1111/exd.13001. Epub 2016 May 18.

PMID:
26990546
9.

Reply to the letter to the editor 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance' by Funck-Brentano et al.

Funck-Brentano E, Alvarez JC, Longvert C, Abe E, Beauchet A, Saiag P, Funck-Brentano C.

Ann Oncol. 2016 Feb;27(2):364-5. doi: 10.1093/annonc/mdv549. Epub 2015 Nov 16. No abstract available.

PMID:
26578725
10.

Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients.

Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dupin N, Descamps V, Aractingi S, Funck-Brentano E, Autier P, Dragomir M, Boniol M.

J Natl Cancer Inst. 2015 Sep 15;107(12):djv264. doi: 10.1093/jnci/djv264. Print 2015 Dec.

11.

Variations of BRAF mutant allele percentage in melanomas.

Hélias-Rodzewicz Z, Funck-Brentano E, Baudoux L, Jung CK, Zimmermann U, Marin C, Clerici T, Le Gall C, Peschaud F, Taly V, Saiag P, Emile JF.

BMC Cancer. 2015 Jul 4;15:497. doi: 10.1186/s12885-015-1515-3.

12.

Re: High nevus counts confer a favorable prognosis in melanoma patients by S ribero and co-workers, published in the International Journal of Cancer, 2015 (online 21 march 2015).

Autier P, Funck-Brentano E, Aegerter P, Boniol M, Saiag P.

Int J Cancer. 2015 Dec 15;137(12):3006-7. doi: 10.1002/ijc.29648. Epub 2015 Jul 22. No abstract available.

13.

Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance.

Funck-Brentano E, Alvarez JC, Longvert C, Abe E, Beauchet A, Funck-Brentano C, Saiag P.

Ann Oncol. 2015 Jul;26(7):1470-5. doi: 10.1093/annonc/mdv189. Epub 2015 Apr 21.

PMID:
25899783
14.

Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.

Ilie M, Long-Mira E, Funck-Brentano E, Lassalle S, Butori C, Lespinet-Fabre V, Bordone O, Gay A, Zahaf K, Poissonnet G, Lacour JP, Bahadoran P, Ballotti R, Gros A, Dutriaux C, Saiag P, Merlio JP, Vergier B, Emile JF, Hofman V, Hofman P.

J Am Acad Dermatol. 2015 May;72(5):786-93. doi: 10.1016/j.jaad.2015.01.012. Epub 2015 Feb 7.

PMID:
25659223
15.

Therapeutic management of DRESS: a retrospective study of 38 cases.

Funck-Brentano E, Duong TA, Bouvresse S, Bagot M, Wolkenstein P, Roujeau JC, Chosidow O, Valeyrie-Allanore L.

J Am Acad Dermatol. 2015 Feb;72(2):246-52. doi: 10.1016/j.jaad.2014.10.032.

PMID:
25592341
16.

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF.

Cancer Immunol Res. 2015 Mar;3(3):254-65. doi: 10.1158/2326-6066.CIR-14-0018. Epub 2014 Nov 17.

17.

Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib.

Guedj M, Quéant A, Funck-Brentano E, Kramkimel N, Lellouch J, Monnet D, Longvert C, Gantzer A, Brézin AP.

JAMA Ophthalmol. 2014 Dec;132(12):1421-5. doi: 10.1001/jamaophthalmol.2014.3024.

PMID:
25125216
18.

A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients.

Alvarez JC, Funck-Brentano E, Abe E, Etting I, Saiag P, Knapp A.

J Pharm Biomed Anal. 2014 Aug;97:29-32. doi: 10.1016/j.jpba.2014.04.014. Epub 2014 Apr 18.

PMID:
24814993
19.

[Nodular cutaneous amyloidosis associated with Sjögren's syndrome].

Elfatoiki FZ, Funck Brentano E, Blanc F, Clerici T, Saiag P.

Ann Dermatol Venereol. 2013 May;140(5):378-81. doi: 10.1016/j.annder.2013.02.014. Epub 2013 Mar 29. French.

PMID:
23663711
20.

[Auto-immune thyroiditis and drug reaction with eosinophilia and systemic symptoms (DRESS) associated with HHV-6 viral reactivation].

Funck-Brentano E, Duong T, Family D, Bouaziz JD, Ortonne N, Bagot M, Roujeau JC, Wolkenstein P, Valeyrie-Allanore L.

Ann Dermatol Venereol. 2011 Aug-Sep;138(8-9):580-5. doi: 10.1016/j.annder.2011.01.048. Epub 2011 Mar 21. French.

PMID:
21893231

Supplemental Content

Loading ...
Support Center